CD38 and Miyoshi myopathy: Based on the clinical achievements of anti-CD38 MoAbs, a role for NAD+ metabolism is also warranted in MM, thus providing basis for further investigations on NAD+ase activity to elucidate the mechanisms of immunotherapy-based approaches.